Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H9N2 virosomal vaccine
- Development stage
- Unknown
- Lead developer
- Robert L. Atmar
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous, Intraocular, Intranasal, Spray
01
Overview
The H9N2 virosomal vaccine is a type of vaccine designed to protect against the H9N2 avian influenza virus. It utilizes a virosomal or virus-like particle (VLP) platform, which consists of reconstituted influenza virus envelopes containing key viral surface proteins, primarily hemagglutinin (HA) and neuraminidase (NA), but lacking the viral genetic material, rendering them non-infectious. These VLPs mimic the natural virus structure, presenting antigens to the immune system to elicit a robust immune response, including the production of neutralizing antibodies and cellular immunity. This mechanism aims to provide protection against H9N2 infection, a significant pathogen in poultry with zoonotic potential. Some formulations may include adjuvants, such as MF59 or ISA70, to enhance immunogenicity.
- Other names
- H9 HA VLP vaccineH-9 HA VLP vaccineH 9 HA VLP vaccineH9N2 VLP vaccineH-9N2 VLP vaccineH 9N2 VLP vaccineH9N2 virus-like particle vaccineH-9N2 virus-like particle vaccineH 9N2 virus-like particle vaccine
02
Targets
H9 HA (Influenza A hemagglutinin H9)Neuraminidase
Beyond the preview
Go deeper on H9N2 virosomal vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H9N2 virosomal vaccine.